EA202193322A1 - Конструирование шарнирной области для управления димеризацией антител - Google Patents
Конструирование шарнирной области для управления димеризацией антителInfo
- Publication number
- EA202193322A1 EA202193322A1 EA202193322A EA202193322A EA202193322A1 EA 202193322 A1 EA202193322 A1 EA 202193322A1 EA 202193322 A EA202193322 A EA 202193322A EA 202193322 A EA202193322 A EA 202193322A EA 202193322 A1 EA202193322 A1 EA 202193322A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dimer
- construction
- hinge region
- mutations
- heavy chains
- Prior art date
Links
- 238000010276 construction Methods 0.000 title abstract 2
- 238000006471 dimerization reaction Methods 0.000 title abstract 2
- 239000000539 dimer Substances 0.000 abstract 3
- 230000035772 mutation Effects 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962854907P | 2019-05-30 | 2019-05-30 | |
| PCT/US2020/035196 WO2020243477A2 (en) | 2019-05-30 | 2020-05-29 | Engineering the hinge region to drive antibody dimerization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202193322A1 true EA202193322A1 (ru) | 2022-03-10 |
Family
ID=72234906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202193322A EA202193322A1 (ru) | 2019-05-30 | 2020-05-29 | Конструирование шарнирной области для управления димеризацией антител |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220235148A1 (enExample) |
| EP (1) | EP3976643A2 (enExample) |
| JP (2) | JP7500619B2 (enExample) |
| KR (1) | KR20220016139A (enExample) |
| CN (2) | CN114174344B (enExample) |
| AU (1) | AU2020283890A1 (enExample) |
| CA (1) | CA3141690A1 (enExample) |
| EA (1) | EA202193322A1 (enExample) |
| MX (1) | MX2021014534A (enExample) |
| SG (1) | SG11202112926YA (enExample) |
| TW (2) | TW202525844A (enExample) |
| WO (1) | WO2020243477A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110669137B (zh) * | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
| WO2022223016A1 (en) * | 2021-04-23 | 2022-10-27 | Chimagen Biosciences, Ltd | Heterodimeric antibodies and antigen-binding fragment thereof |
| KR20250051674A (ko) * | 2022-07-22 | 2025-04-17 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 다중특이적 항체의 중쇄 및 경쇄의 상동성 페어링을 촉진하는 돌연변이체 |
| CN115232214A (zh) * | 2022-08-16 | 2022-10-25 | 广州市拜沃思生物科技有限公司 | 一种双特异性抗体及其制备方法和应用 |
| TW202506725A (zh) * | 2023-04-07 | 2025-02-16 | 美商麥迪紐有限責任公司 | 三特異性工程化抗體 |
| WO2024242490A1 (ko) * | 2023-05-24 | 2024-11-28 | 삼성바이오로직스 주식회사 | Ch3 도메인 변이체 또는 이를 포함하는 이중 특이적 항체 |
| WO2025167974A1 (zh) * | 2024-02-07 | 2025-08-14 | 上海齐鲁制药研究中心有限公司 | 多特异性抗体或抗原结合片段 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30985A (en) | 1860-12-18 | Thomas l | ||
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| CA2111348A1 (en) | 1991-06-14 | 1992-12-23 | John S. Logan | Production of human hemoglobin in transgenic pigs |
| EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2003025020A1 (en) | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Method of constructing camel antibody library |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2007227292B2 (en) | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
| IN2009DN05758A (enExample) | 2007-03-12 | 2015-07-24 | Esbatech Ag | |
| ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| US8793074B2 (en) | 2007-06-21 | 2014-07-29 | Saint Louis University | Sequence covariance networks, methods and uses therefor |
| PL2158315T3 (pl) | 2007-06-25 | 2016-10-31 | Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych | |
| CN102369215B (zh) * | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | 包含全长抗体和单链Fab片段的多特异性抗体 |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| WO2011143545A1 (en) * | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| WO2011147986A1 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
| EP4011913A1 (en) * | 2011-06-30 | 2022-06-15 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| SI2771364T1 (sl) | 2011-10-27 | 2019-10-30 | Genmab As | Produkcija heterodimernih proteinov |
| CA2859755C (en) * | 2011-12-23 | 2021-04-20 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| RU2655439C2 (ru) * | 2013-05-31 | 2018-05-28 | Займворкс Инк. | Гетеромультимеры с уменьшенной или подавленной эффекторной функцией |
| JP6509852B2 (ja) * | 2013-07-31 | 2019-05-08 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）の構築物 |
| WO2015173756A2 (en) * | 2014-05-16 | 2015-11-19 | Pfizer Inc. | Bispecific antibodies |
| WO2018030806A1 (ko) * | 2016-08-10 | 2018-02-15 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
-
2020
- 2020-05-29 AU AU2020283890A patent/AU2020283890A1/en active Pending
- 2020-05-29 WO PCT/US2020/035196 patent/WO2020243477A2/en not_active Ceased
- 2020-05-29 US US17/615,555 patent/US20220235148A1/en active Pending
- 2020-05-29 EP EP20761358.9A patent/EP3976643A2/en active Pending
- 2020-05-29 KR KR1020217042483A patent/KR20220016139A/ko active Pending
- 2020-05-29 EA EA202193322A patent/EA202193322A1/ru unknown
- 2020-05-29 SG SG11202112926YA patent/SG11202112926YA/en unknown
- 2020-05-29 CN CN202080054199.XA patent/CN114174344B/zh active Active
- 2020-05-29 CN CN202411591082.1A patent/CN119431599A/zh active Pending
- 2020-05-29 MX MX2021014534A patent/MX2021014534A/es unknown
- 2020-05-29 CA CA3141690A patent/CA3141690A1/en active Pending
- 2020-05-29 TW TW114109900A patent/TW202525844A/zh unknown
- 2020-05-29 JP JP2021570175A patent/JP7500619B2/ja active Active
- 2020-05-29 TW TW109118067A patent/TWI879770B/zh active
-
2024
- 2024-06-04 JP JP2024090480A patent/JP2024113040A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020283890A1 (en) | 2021-12-16 |
| TW202110877A (zh) | 2021-03-16 |
| MX2021014534A (es) | 2022-02-11 |
| TW202525844A (zh) | 2025-07-01 |
| US20220235148A1 (en) | 2022-07-28 |
| CA3141690A1 (en) | 2020-12-03 |
| JP2024113040A (ja) | 2024-08-21 |
| CN114174344B (zh) | 2024-11-22 |
| KR20220016139A (ko) | 2022-02-08 |
| WO2020243477A3 (en) | 2021-01-07 |
| CN114174344A (zh) | 2022-03-11 |
| TWI879770B (zh) | 2025-04-11 |
| EP3976643A2 (en) | 2022-04-06 |
| WO2020243477A2 (en) | 2020-12-03 |
| JP2022534901A (ja) | 2022-08-04 |
| JP7500619B2 (ja) | 2024-06-17 |
| SG11202112926YA (en) | 2021-12-30 |
| CN119431599A (zh) | 2025-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202193322A1 (ru) | Конструирование шарнирной области для управления димеризацией антител | |
| SA521422370B1 (ar) | Fab بروتينات ربط متعددة النوعية ذات مجالات متحولة | |
| PE20211055A1 (es) | Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas | |
| PE20190450A1 (es) | Anticuerpos anti-pd-1, un metodo de produccion y un metodo para su uso | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| EA201891121A1 (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения | |
| DOP2019000011A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| EA202090812A1 (ru) | Новые биспецифические полипептидные комплексы | |
| EA201692476A1 (ru) | Модифицированные антигенсвязывающие полипептидные конструкции и их применение | |
| PE20200148A1 (es) | Anticuerpos anti-trem2 y metodos para utilizarlos | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| EA201990285A1 (ru) | Гетеродимерные иммуноглобулиновые конструкции и способы их получения | |
| PE20120549A1 (es) | Proteinas biespecificas de union a antigenos | |
| CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
| BR112015023431A2 (pt) | moléculas fc biespecíficas | |
| PE20091172A1 (es) | Anticuerpos bivalentes biespecificos | |
| CR20180311A (es) | Aglutinantes de tnf mejorados | |
| BR112015000798A2 (pt) | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 | |
| ECSP23053070A (es) | Anticuerpos multiespecíficos con especificidad para il-4r e il-31 | |
| CO2020001654A2 (es) | Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados |